Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: DNA Sciences Withdraws $125M IPO

NEW YORK, July 19 - Population genetics company DNA Sciences has withdrawn its initial public offering for $125 million in common stock, according to a filing Thursday with the Securities and Exchange Commission.

The company first filed for an IPO on January 5, saying at the time that it planned to use the money to expand its studies on the role genes play in diseases such as cancer, asthma, and diabetes, bolster its genetic database, and to commercialize diagnostic tests for common diseases. In addition, the company said it planned to subscribe to genetic databases and fund corporate expenses.

Today, however, a company spokeswoman said that with the public financial markets' uncertain reaction to an IPO, the company had turned its attention to seeking longer-term financing, through collaborations and alliances with other businesses.

"There's no advantage to keeping the filing open," the spokeswoman said.

Since its founding in 1998, DNA Sciences, based in Fremont, Calif., has raised about $120 million in venture funding. The company currently has a partnership with Amersham Pharmacia Biotech to develop new technology for DNA sequencing, and provides genotyping and pharmacogenetic services to 18 pharmaceutical companies through its PPGx subsidiary, which the company acquired in December 2000.

In May, Celera announced that DNA Science had subscribed to its databases through the Celera Discovery System.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.